Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings, Inc. (HRMY)
:HRMY
RESEARCH TOOLSreports
HRMY Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HRMY Stock 12 Month Forecast
Average Price Target
$52.67
▲(50.74% Upside)
| Highest Price Target$70.00 | Average Price Target$52.67 | Lowest Price Target$33.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$39
Buy
11.62%
Upside
Reiterated
07/10/25
Harmony Biosciences Holdings scores well due to its strong financial performance, supported by impressive revenue growth and profitability. The company’s strategic initiatives and robust pipeline contribute significantly to its positive outlook. However, technical indicators suggest caution, with the stock nearing overbought levels. Valuation remains attractive, and recent corporate events further enhance its market position.
Truist Financial
―
Buy
―
Reiterated
08/06/25
Needham
$49
Buy
40.24%
Upside
Reiterated
08/06/25
Mizuho Securities
$48
Buy
37.38%
Upside
Reiterated
08/05/25
H.C. Wainwright
$70
Buy
100.34%
Upside
Reiterated
07/21/25
Harmony Biosciences Holdings: Promising Growth Trajectory with Strong Leadership and Robust Pipeline Supports Buy RatingValuation and Risks. We assess Harmony using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, ZYN002 in FXN of 50%, (22q11.2 deletion) syndrome of 25%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3.9B and price target of $70.
Goldman Sachs
$33
Hold
-5.55%
Downside
Initiated
07/10/25
Deutsche Bank
$54→$55
Buy
57.41%
Upside
Reiterated
07/10/25
Oppenheimer
$61
Buy
74.59%
Upside
Initiated
06/02/25
Bank of America Securities
$32→$31
Sell
-11.28%
Downside
Reiterated
05/06/25
UBS
$55→$48
Buy
37.38%
Upside
Reiterated
04/28/25
Cantor Fitzgerald
$54
Buy
54.55%
Upside
Reiterated
02/25/25
Piper Sandler
$44→$48
Buy
37.38%
Upside
Reiterated
12/05/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$39
Buy
11.62%
Upside
Reiterated
07/10/25
Harmony Biosciences Holdings scores well due to its strong financial performance, supported by impressive revenue growth and profitability. The company’s strategic initiatives and robust pipeline contribute significantly to its positive outlook. However, technical indicators suggest caution, with the stock nearing overbought levels. Valuation remains attractive, and recent corporate events further enhance its market position.
Truist Financial
―
Buy
―
Reiterated
08/06/25
Needham
$49
Buy
40.24%
Upside
Reiterated
08/06/25
Mizuho Securities
$48
Buy
37.38%
Upside
Reiterated
08/05/25
H.C. Wainwright
$70
Buy
100.34%
Upside
Reiterated
07/21/25
Harmony Biosciences Holdings: Promising Growth Trajectory with Strong Leadership and Robust Pipeline Supports Buy RatingValuation and Risks. We assess Harmony using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, ZYN002 in FXN of 50%, (22q11.2 deletion) syndrome of 25%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3.9B and price target of $70.
Goldman Sachs
$33
Hold
-5.55%
Downside
Initiated
07/10/25
Deutsche Bank
$54→$55
Buy
57.41%
Upside
Reiterated
07/10/25
Oppenheimer
$61
Buy
74.59%
Upside
Initiated
06/02/25
Bank of America Securities
$32→$31
Sell
-11.28%
Downside
Reiterated
05/06/25
UBS
$55→$48
Buy
37.38%
Upside
Reiterated
04/28/25
Cantor Fitzgerald
$54
Buy
54.55%
Upside
Reiterated
02/25/25
Piper Sandler
$44→$48
Buy
37.38%
Upside
Reiterated
12/05/24
Best Analysts Covering Harmony Biosciences Holdings
1 Month
xxx
Success Rate
8/13 ratings generated profit
Average Return
-4.45%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of -4.45% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
Average Return
-0.18%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of -0.18% per trade.
1 Year
Success Rate
7/13 ratings generated profit
Average Return
-0.12%
reiterated a buy rating 8 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -0.12% per trade.
2 Years
xxx
Success Rate
7/13 ratings generated profit
Average Return
-0.25%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of -0.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HRMY Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
8
7
10
8
6
Buy
11
8
11
17
13
Hold
0
0
0
1
1
Sell
4
2
2
1
0
Strong Sell
0
0
0
0
0
total
23
17
23
27
20
Each month's total comprises the sum of three months' worth of ratings.
HRMY Financial Forecast
HRMY Stock Forecast FAQ
What is HRMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Harmony Biosciences Holdings, Inc.’s 12-month average price target is 52.67.
What is HRMY’s upside potential, based on the analysts’ average price target?
Harmony Biosciences Holdings, Inc. has 50.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HRMY a Buy, Sell or Hold?
Harmony Biosciences Holdings, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Harmony Biosciences Holdings, Inc.’s price target?
The average price target for Harmony Biosciences Holdings, Inc. is 52.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $33.00. The average price target represents 50.74% Increase from the current price of $34.94.
The highest analyst price target is $70.00 ,the lowest forecast is $33.00. The average price target represents 50.74% Increase from the current price of $34.94.
What do analysts say about Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of HRMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.